英国的一项研究测试AI, 利用生物检查数据和长期患者结果,改进前列腺癌治疗决策。 A UK study tests AI to improve prostate cancer treatment decisions using biopsy data and long-term patient outcomes.

牛津大学领导的一项由前列腺癌英国资助的新研究正在测试人工智能是否可以通过分析至少五年患者随访数据的活检样本来改善前列腺癌治疗决策. A new University of Oxford-led study, funded by Prostate Cancer UK, is testing whether AI can improve prostate cancer treatment decisions by analyzing biopsy samples with at least five years of patient follow-up data. " 前方路径 " 研究涉及三个全国保健服务站点,旨在帮助医生更好地评估癌症侵袭性,有可能减少不必要的外科手术或放射治疗。 The Vanguard Path study, involving three NHS sites, aims to help doctors better assess cancer aggressiveness, potentially reducing unnecessary surgeries or radiotherapy. Artera开发的AI工具将在真正的临床环境中进行评估,尤其是在治疗决定不确定的情况下。 The AI tool, developed by Artera, will be evaluated in real clinical settings, particularly where treatment decisions are uncertain. 在这项努力之后,国家保健服务系统又进行了一次试验,利用AI将高风险磁共振扫描列为优先事项,以便更快地进行诊断。 This effort follows another NHS trial using AI to prioritize high-risk MRI scans for faster diagnosis. 前列腺癌是男性最常见的癌症,2024年英格兰诊断了58,000多例。 Prostate cancer, the most common cancer in men, had over 58,000 diagnoses in England in 2024. 研究人员说,这项研究可以提供关键证据,证明国民保健制度在前列腺癌护理中更广泛地采用AI。 Researchers say the study could provide key evidence for wider NHS adoption of AI in prostate cancer care.